secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-08-21T23:59:59+00:00
Accession:  0001437749-24-027432
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar receives HREC clearance in Australia for Phase 1 trial of MNPR-101-Lu in advanced cancers
--------------------------------------------------------------------------------

- HREC clearance in Australia to commence Phase 1 therapeutic trial of MNPR-101-Lu (Lu-177 with anti-uPAR antibody).
- Trial will enroll patients with advanced solid cancers, including triple negative breast and pancreatic cancer.
- Preclinical data showed complete tumor elimination in human pancreatic cancer xenograft model after single injection.
- MNPR-101-Lu is a therapeutic follow-on to the ongoing MNPR-101-Zr imaging and dosimetry trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924027432/0001437749-24-027432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924027432/mnpr20240820_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-027432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer